arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Cogent Biosciences, Inc.

COGT Health Care Biotechnology: Pharmaceutical Preparations
$34.78
▲ +0.1% Today
as of Sep 4, 16:47 ET
Last 30 days -14.53% Jul 28 → Sep 04
$33.91 $36.31 $38.70 $41.10 $43.50 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$34.56
High
$35.20
Low
$34.42
Volume
$784,063
Avg Vol
$2M
Mkt Cap
$6.5B
P/E (TTM)
—
Beta
—
52w High
$43.73
52w Low
$11.60
Div Yield
—
Shares Out
$172M

Recent Press Releases & News last 60 days · 5 items

Sep 2 · 21:33 MT Newswires
Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia
Aug 31 · 21:08 MT Newswires
Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing
Aug 13 · 13:55 Zacks
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
▸ Show all 5 press releases & news Free account →

Overview

52-week range
$12
$44
72% of range
Avg surprise (last 3)
+3.6%
Avg reaction (last 2)
-7.5%
50% positive
Latest IV / EM
70%
EM ±11.0% · $35 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.64$-0.59$-0.54$-0.48$-0.43 Actual $-0.55Actual $-0.59Actual $-0.64Actual $-0.49Actual $-0.43Actual $-0.52Actual $-0.52Est $-0.56Actual $-0.53Est $-0.55Actual $-0.50Actual $-0.53Est $-0.53Actual $-0.52 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-97M$-92M$-86M$-80M$-74M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.52 — — — — financials
Tue May 5, 2026Mar/2026 $-0.53 $-0.53 0.0% -1.9% +0.7% earnings
Tue Sep 30, 2025Sep 2025 $-0.50 — — — — financials
Tue Aug 5, 2025Jun/2025 $-0.53 $-0.55 +3.6% — — earnings
Tue May 6, 2025Mar/2025 $-0.52 $-0.56 +7.1% — -15.6% earnings
Mon Sep 30, 2024Sep 2024 $-0.52 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.43 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.49 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.64 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.59 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.55 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-103M$-104M—$-83M$-76M$-75M—$-75M
Net income$-96M$-97M—$-81M$-74M$-72M—$-71M
EPS (diluted)$-0.52$-0.53—$-0.50$-0.53$-0.52—$-0.52

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$181M$241M$312M$125M$128M$126M$98M$97M
Inventory————————
Total current assets$805M$878M$910M$397M$245M$253M$296M$342M
Total assets$835M$903M$938M$426M$275M$284M$328M$384M
Long-term debt$223M$223M—$44M$44M—$0—
Total liabilities$302M$295M$301M$123M$120M$65M$72M$69M
Total equity$532M$608M$636M$302M$155M$219M$256M$315M

Implied volatility — last 90 days

37%116%196%275%355% Jun 07 — IV 77% · EM ±10.7%Jun 08 — IV 91% · EM ±12.0%Jun 09 — IV 105% · EM ±13.2%Jun 10 — IV 89% · EM ±10.5%Jun 11 — IV 89% · EM ±9.8%Jun 12 — IV 52% · EM ±5.3%Jun 15 — IV 92% · EM ±6.6%Jun 16 — IV 60% · EM ±3.6%Jun 17 — IV 355% · EM ±14.8%Jun 19 — IV 58% · EM ±12.7%Jun 22 — IV 64% · EM ±13.4%Jun 23 — IV 68% · EM ±13.9%Jun 24 — IV 68% · EM ±13.6%Jun 25 — IV 60% · EM ±11.8%Jun 29 — IV 76% · EM ±13.4%Jun 30 — IV 65% · EM ±11.2%Jul 01 — IV 49% · EM ±8.1%Jul 02 — IV 62% · EM ±10.0%Jul 03 — IV 64% · EM ±10.0%Jul 06 — IV 79% · EM ±11.0%Jul 07 — IV 44% · EM ±5.8%Jul 08 — IV 70% · EM ±8.8%Jul 09 — IV 70% · EM ±8.3%Jul 10 — IV 42% · EM ±4.7%Jul 13 — IV 62% · EM ±5.1%Jul 14 — IV 74% · EM ±5.4%Jul 15 — IV 73% · EM ±4.3%Jul 20 — IV 66% · EM ±15.7%Jul 21 — IV 52% · EM ±12.1%Jul 22 — IV 56% · EM ±12.7%Jul 23 — IV 53% · EM ±11.9%Jul 24 — IV 50% · EM ±11.0%Jul 27 — IV 53% · EM ±11.1%Jul 28 — IV 65% · EM ±13.3%Jul 29 — IV 68% · EM ±13.6%Jul 30 — IV 69% · EM ±13.5%Jul 31 — IV 57% · EM ±11.0%Aug 03 — IV 73% · EM ±13.0%Aug 04 — IV 73% · EM ±12.6%Aug 05 — IV 79% · EM ±13.2%Aug 06 — IV 76% · EM ±12.3%Aug 07 — IV 65% · EM ±10.1%Aug 10 — IV 95% · EM ±13.2%Aug 11 — IV 56% · EM ±7.4%Aug 12 — IV 62% · EM ±7.8%Aug 13 — IV 80% · EM ±9.5%Aug 14 — IV 73% · EM ±8.1%Aug 17 — IV 77% · EM ±6.5%Aug 18 — IV 78% · EM ±5.6%Aug 19 — IV 80% · EM ±4.7%Aug 20 — IV 129% · EM ±5.4%Aug 24 — IV 59% · EM ±12.4%Aug 25 — IV 38% · EM ±7.7%Aug 26 — IV 67% · EM ±13.5%Aug 27 — IV 55% · EM ±10.7%Aug 28 — IV 67% · EM ±12.8%Aug 31 — IV 76% · EM ±13.4%Sep 01 — IV 56% · EM ±9.7%Sep 02 — IV 85% · EM ±14.2%Sep 03 — IV 69% · EM ±11.1%Sep 04 — IV 70% · EM ±11.0%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in